Interleukin Testing

Comprehensive Interleukin Testing: High‑Sensitivity Multiplex Immunoassay, Functional Neutralisation, and Phospho‑Signalling Profiling for Cytokine‑Driven Disease Management

Interleukins (ILs) constitute a large and functionally diverse family of cytokines that orchestrate immune cell communication, inflammation, haematopoiesis, and tissue homeostasis. With over 40 distinct members (IL‑1 to IL‑40), each exhibiting pleiotropic, redundant, or antagonistic effects, the accurate measurement and functional interpretation of interleukins are essential for understanding the pathophysiology of autoimmune diseases, chronic inflammatory conditions, infections, and malignancies. Clinicians and researchers seek interleukin testing not merely to quantify a single cytokine but to obtain a comprehensive, multiplexed profile that reflects the net balance of pro‑inflammatory, anti‑inflammatory, and regulatory signals in a given patient. Moreover, functional assays that assess the biological activity of interleukins—rather than only their immunoreactive mass—are increasingly recognised as critical for predicting therapeutic responses, monitoring biologics, and stratifying patients for targeted immunotherapy. Our laboratory provides a fully integrated interleukin testing service that combines ultrasensitive multiplex chemiluminescent immunoassays, cell‑based functional bioassays, and intracellular phospho‑signalling cytometry, delivering an unprecedented depth of analytical and biological insight for precision immunology.

The Clinical Rationale for Multiplex and Functional Interleukin Profiling

Conventional single‑analyte ELISA or bead‑based immunoassays can measure the concentration of individual interleukins, but they fail to capture the simultaneous interplay of multiple cytokines that determine the net inflammatory or regulatory outcome. Furthermore, immunoassays measure the total protein mass, which may include inactive precursor forms, degraded fragments, or complexed species that do not reflect biological activity. For instance, IL‑1β is synthesised as an inactive pro‑form and requires inflammasome‑mediated cleavage for bioactivity; IL‑2 can be neutralised by soluble CD25; and IL‑6 may exist in a complex with its soluble receptor that enhances signalling. Our core interleukin panel includes quantitative measurement of IL‑1β, IL‑2, IL‑4, IL‑5, IL‑6, IL‑7, IL‑8, IL‑10, IL‑12p70, IL‑13, IL‑17A, IL‑18, IL‑21, IL‑22, IL‑23, and IL‑33 using a validated multiplex chemiluminescent array with limits of quantification (LOQs) in the sub‑pg/mL range for most analytes. This panel is designed to cover the major Th1, Th2, Th17, Treg, and innate cytokine axes, enabling a comprehensive snapshot of the inflammatory landscape.

To complement concentration data, we offer functional bioassays for key interleukins such as IL‑2 (using CTLL‑2 or Kit225 cells to measure proliferation), IL‑6 (B9 or 7TD1 hybridoma growth assay), IL‑10 (MC/9 mast cell line co‑stimulation assay), and IL‑17 (CHO‑K1 cells expressing IL‑17 receptor with NF‑κB reporter). These bioassays quantify the biological activity of the endogenous cytokine, expressed as international units (IU/mL) referenced to WHO standards. For samples from patients on biologic therapies (e.g., anti‑IL‑6 or anti‑IL‑17 antibodies), we provide a neutralisation assay that measures the residual bioactivity after addition of a specific blocking antibody, allowing us to estimate the amount of active cytokine that is not neutralised by the drug—a parameter that predicts clinical response better than drug trough levels alone. Additionally, we perform intracellular phospho‑flow cytometry to assess signalling pathway activation (e.g., pSTAT3 for IL‑6, pSTAT5 for IL‑2, pSTAT4 for IL‑12) in peripheral blood mononuclear cells (PBMCs), providing a direct functional readout of cytokine signalling at the single‑cell level, which is invaluable for immunomonitoring in clinical trials and for diagnosing primary immunodeficiencies with defective cytokine signalling.

Our Analytical Capabilities: Sensitivity, Multiplexing, and Functional Integration

Our primary immunoassay platform is a fully automated, magnetic bead‑based multiplex chemiluminescent system that simultaneously quantifies up to 18 interleukins and related cytokines in a single 25‑µL sample, with dynamic ranges spanning 3–4 orders of magnitude. The assay uses rigorously validated monoclonal antibody pairs specific to each human interleukin, with demonstrated cross‑reactivity <0.1% to other family members and to common heterophilic interferences. Inter‑assay precision (CV) is consistently below 8% for all analytes, and we employ a five‑parameter logistic regression for curve fitting, with built‑in quality controls for each run. For samples with suspected matrix effects (e.g., rheumatoid factor, heterophilic antibodies), we perform a dilutional linearity check and, if needed, confirm results using a separate single‑plex electrochemiluminescence assay or LC‑MS/MS for selected interleukins (IL‑6, IL‑1β) as a reference.

Our functional bioassays are performed in a dedicated GLP‑compliant cell culture facility, using validated reporter cell lines that are routinely authenticated and tested for mycoplasma and response consistency. Each assay includes a reference standard curve (WHO international standard), a positive control, a negative control, and a matrix spike recovery test. We report results in international units (IU) per mL, with LOQs typically between 0.1 and 1 IU/mL depending on the analyte. For the neutralisation assay, we pre‑incubate the patient sample with saturating amounts of the relevant anti‑cytokine antibody (e.g., tocilizumab for IL‑6) and measure the residual bioactivity; the percentage inhibition is calculated, and a value < 50% inhibition indicates the presence of excess free cytokine that may not be fully controlled by the therapy. Our intracellular phospho‑signalling assay uses flow cytometry with phospho‑specific antibodies (e.g., p‑STAT3, p‑STAT5, p‑STAT4, p‑p38) and a comprehensive gating strategy for T‑cell subsets, monocytes, and NK cells, providing a detailed signalling activity index that correlates with clinical disease activity.

Regulatory Compliance and Quality Assurance

All interleukin testing services are conducted under CLIA '88 and CAP accreditation, with immunoassays validated in accordance with CLSI EP‑A2, EP‑A5, and EP‑A9 guidelines. Our cell‑based bioassays follow the principles of ICH Q2(R1) for biological assay validation, including assessment of precision, accuracy, linearity, and robustness. We participate in external proficiency testing for cytokine immunoassays (UK NEQAS, CAP) and for selected bioassays where available. For each patient report, we provide not only the quantitative concentrations and bioactivity values but also a cytokine balance score (pro‑inflammatory vs. regulatory ratio), a functional activity index (bioactivity/concentration ratio), and a signalling activation score derived from the phospho‑flow data. Additionally, we include a comprehensive interpretive narrative that highlights pattern associations (e.g., Th17‑predominant, Th2‑associated, or regulatory‑dominant), suggests potential therapeutic vulnerabilities, and recommends follow‑up tests when appropriate.

Our Distinctive Advantages in Interleukin Testing

Our laboratory offers several unique attributes that set us apart from conventional cytokine testing providers. First, we provide a truly integrated “triple‑layer” assessment—concentration (multiplex immunoassay), function (cell‑based bioactivity), and signalling (intracellular phospho‑flow)—all from a single sample, offering a comprehensive view of the interleukin network that is unmatched in the commercial space. Second, our multiplex panel is customisable; we can adapt the cytokine menu to include emerging interleukins (e.g., IL‑36, IL‑37, IL‑38) or exclude analytes based on the clinical or research question, providing flexibility for both routine diagnostics and exploratory studies. Third, our neutralisation and residual activity assays are directly applicable to patients on biologic therapies, enabling evidence‑based dose adjustment and early detection of loss of response due to immunogenicity or excess target production.

Fourth, our phospho‑signalling profiling is performed on cryopreserved PBMCs with strict standardisation, and we have established a large reference database of healthy controls and disease‑specific cohorts, allowing us to report a patient’s signalling activity in percentile terms and to detect aberrant responses that may not be apparent from cytokine concentrations alone. Fifth, we provide longitudinal monitoring packages with automated trend analysis, graphical overlays of multiple visits, and alert thresholds for significant changes in the cytokine balance score or signalling index, which have been shown to predict disease flares and treatment failure in autoimmune and chronic inflammatory diseases. Our expert immunology team is available for in‑depth case consultations, assisting clinicians in integrating the complex interleukin profile with clinical history and other laboratory findings to guide personalised therapeutic strategies.

Specimen Types and Clinical Applications

Our interleukin testing is validated on serum, plasma (EDTA, heparin, citrate), and cell culture supernatants. For phospho‑signalling, we require peripheral blood collected in heparinised tubes and processed within 6 hours, or we provide a PBMC isolation kit with stabilising media for overnight shipment. Clinical applications span the diagnosis and monitoring of autoimmune diseases (rheumatoid arthritis, lupus, psoriasis, inflammatory bowel disease), the assessment of cytokine release syndromes (e.g., CRS in CAR‑T therapy), the evaluation of primary and secondary immunodeficiencies, the prediction of graft‑versus‑host disease, and the therapeutic monitoring of cytokine‑targeting biologics (IL‑6, IL‑17, IL‑23, IL‑1, IL‑2, IL‑4/13 inhibitors). In oncology, our integrated IL‑2 and IL‑12 functional assays are used to evaluate the immune activating capacity of checkpoint inhibitors, while our IL‑6/IL‑10 balance helps identify patients at risk of immune‑related adverse events.

Innovation and Research Partnerships

We are actively developing high‑dimensional mass cytometry (CyTOF) panels for simultaneous measurement of over 30 cytokines and intracellular phospho‑proteins at the single‑cell level, and we are validating a microfluidic digital ELISA platform for ultra‑sensitive detection of low‑abundance interleukins in cerebrospinal fluid and bronchoalveolar lavage. Our research collaborations with academic centres contribute to the establishment of dynamic reference ranges and to the identification of novel cytokine signatures associated with treatment response and disease progression. We regularly publish our findings and participate in international standardisation efforts, ensuring our testing services remain at the forefront of evidence‑based immunology.

Client Support and Service Model

We provide end‑to‑end support, including custom collection kits, pre‑paid shipping, and flexible scheduling for repeat testing. Our standard turnaround time is 24‑48 hours for the multiplex immunoassay, 48‑72 hours for functional bioassays, and 72‑96 hours for the complete integrated report with phospho‑signalling. Urgent STAT options are available for acute scenarios such as cytokine storm. All results are delivered via a secure electronic portal with interactive visualisations and trend charts. We offer volume‑based discounts, free courier collection, and dedicated project management for multi‑centre trials. We also provide educational webinars and decision‑support algorithms to help clinicians navigate the complexity of interleukin data and incorporate it into routine practice.

Conclusion: Interleukin Testing as a Comprehensive Immune Network Assessment

Interleukin testing, when conducted with multiplex precision, functional bioactivity measurement, and downstream signalling analysis, transforms from a simple cytokine snapshot into a dynamic and integrative assessment of the immune system's operational state. Our laboratory delivers this comprehensive solution—combining high‑sensitivity multiplex immunoassay, cell‑based functional bioassays, intracellular phospho‑signalling profiling, and expert clinical interpretation—to empower clinicians with the actionable insights necessary for precision immunotherapy, early diagnosis of immune dysregulation, and personalised management of inflammatory and autoimmune diseases. Whether the clinical question involves characterising the inflammatory endotype of a rheumatoid arthritis patient, monitoring anti‑IL‑17 therapy, or diagnosing a primary immunodeficiency with aberrant cytokine signalling, our services provide the accuracy, depth, and clinical relevance required for optimal decision‑making.

We invite you to partner with us for your interleukin testing needs. Our dedicated immunology team is ready to assist with test selection, custom panel design, and result interpretation, ensuring you receive not only reliable laboratory data but also a strategic framework for integrating cytokine and signalling biomarkers into your patient care pathways. Choose our laboratory for excellence in cytokine analytics, backed by scientific rigour, technological innovation, and an unwavering commitment to quality.